NEW YORK (360Dx) – Oxford Gene Technology announced today the US Food and Drug Administration has granted de novo classification for eight of the company's Cytocell Aquarius Haematology fluorescence in situ hybridization probes for acute myeloid leukemia and myelodysplastic syndromes.

The probes reduce the level of validation needed in laboratories and provide accurate, easy-to-interpret detection of chromosomal rearrangements reported in AML and MDS, according to UK-based OGT.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.